Compare Bristol-Myers Squibb Co (BMY) vs United States Copper Index Fund (CPER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs United States Copper Index Fund — how do they compare? Bristol-Myers Squibb Co trades at $63.73 (market cap $129.94B), while United States Copper Index Fund trades at $40.32. The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while United States Copper Index Fund pays none. Which is the better fit depends on your goals.
| BMY | CPER | |
|---|---|---|
Market Cap | $129.94B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $65.89 | $40.85 |
52-Week Low | $42.60 | $27.57 |
Enterprise Value | $163.92B | — |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.
CPER (United States Copper Index Fund) trades at $40.345, up 0.41% with a bullish technical signal supported by moving averages. The copper market faces supply constraints from Chilean weather disruptions while AI and electrification demand drives prices to record highs. Recent news highlights copper's structural bull case with Citi targeting $15,000/tonne by year-end.
Copper's fundamental outlook remains strong due to AI infrastructure demand and supply constraints, though substitution risks and geopolitical tensions present headwinds. The ETF offers pure copper exposure amid favorable analyst sentiment, with technical indicators suggesting continued upward momentum near key resistance levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About United States Copper Index Fund
CPER is a commodity ETF that tracks the price of copper futures via the SummerHaven Copper Index. It provides direct exposure to the 'red metal' using a rules-based strategy to select futures contracts, making it a key tool for hedging or betting on industrial growth and electrification.
Read more on CPER →
